Abstract

Simple SummaryMetastatic lesions in bone tissue are a common complication in breast and prostate cancer patients, accounting for the larger part of pain and suffering in late-stage cancer. The metastatic cancer cells that form these lesions must travel from the primary tumour to a distant bone and enter a mechanically active environment that is largely regulated in response to physical exercise by bone cells known as osteocytes. This study used cell culture techniques to investigate if osteocytes can regulate breast and prostate cancer cells, and how mechanical stimulation of these sensitive bone cells affects cancer cell behaviour. Osteocytes signalled for decreased proliferation of cancer cells, but mechanical stimulation reversed this in breast cancer. By developing a microfluidic organ-chip model, we demonstrated the feasibility and importance of replicating the mechanical tumour microenvironment, finding increased invasion of cancer cells with mechanical stimulation.Breast and prostate cancers preferentially metastasise to bone tissue, with metastatic lesions forming in the skeletons of most patients. On arriving in bone tissue, disseminated tumour cells enter a mechanical microenvironment that is substantially different to that of the primary tumour and is largely regulated by bone cells. Osteocytes, the most ubiquitous bone cell type, orchestrate healthy bone remodelling in response to physical exercise. However, the effects of mechanical loading of osteocytes on cancer cell behaviour is still poorly understood. The aim of this study was to characterise the effects of osteocyte mechanical stimulation on the behaviour of breast and prostate cancer cells. To replicate an osteocyte-controlled environment, this study treated breast (MDA-MB-231 and MCF-7) and prostate (PC-3 and LNCaP) cancer cell lines with conditioned media from MLO-Y4 osteocyte-like cells exposed to mechanical stimulation in the form of fluid shear stress. We found that osteocyte paracrine signalling acted to inhibit metastatic breast and prostate tumour growth, characterised by reduced proliferation and invasion and increased migration. In breast cancer cells, these effects were largely reversed by mechanical stimulation of osteocytes. In contrast, conditioned media from mechanically stimulated osteocytes had no effect on prostate cancer cells. To further investigate these interactions, we developed a microfluidic organ-chip model using the Emulate platform. This new organ-chip model enabled analysis of cancer cell migration, proliferation and invasion in the presence of mechanical stimulation of osteocytes by fluid shear stress, resulting in increased invasion of breast and prostate cancer cells. These findings demonstrate the importance of osteocytes and mechanical loading in regulating cancer cell behaviour and the need to incorporate these factors into predictive in vitro models of bone metastasis.

Highlights

  • Breast and prostate are the two most prevalent cancer types worldwide, with the vast majority of these 1 million combined annual deaths related to metastatic disease [1].Bone tissue is generally one of the most common tumour metastasis sites, with over450,000 patients currently suffering from this condition in the US [2]

  • Addition of unstimulated conditioned media from MLO-Y4 osteocyte-like cells resulted in significantly reduced proliferation, in both breast cancer cell lines and both prostate cancer cell lines (Figure 1B)

  • This was shown by a significant increase in proliferation compared to breast cancer cells treated with conditioned media from unloaded osteocytes

Read more

Summary

Introduction

450,000 patients currently suffering from this condition in the US [2] This is true for breast and prostate cancer, with 65–75% of breast and prostate metastatic patients developing skeletal lesions, together accounting for more than 80% of all cases of metastatic bone disease [3,4]. Once tumour metastasis has been diagnosed, five-year patient survival rates in the UK decrease from 90–98%. Upon discovery of bone metastases, prognosis is poor, with a median survival time of 1–4 years in breast and prostate cancer patients [3]. Bone metastases are the largest contributor to patient suffering and mortality for breast and prostate cancer patients, and yet how these tumours establish a presence in bone remains poorly understood

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call